特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
520767

ガンマアミノ酪酸受容体サブユニットアルファ5:パイプライン製品の分析

Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 - Pipeline Review, H2 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 48 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
ガンマアミノ酪酸受容体サブユニットアルファ5:パイプライン製品の分析
出版日: 2020年09月30日
発行: Global Markets Direct
ページ情報: 英文 48 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、ガンマアミノ酪酸受容体サブユニットアルファ5を標的とした治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

ガンマアミノ酪酸受容体サブユニットアルファ5;概要

ガンマアミノ酪酸受容体サブユニットアルファ5;治療薬の開発

  • 開発中の製品:開発段階別
  • 開発中の製品:治療領域別
  • 開発中の製品:症状別
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • AgeneBio Inc
  • F. Hoffmann-La Roche Ltd
  • Les Laboratoires Servier SAS

薬剤プロファイル

休止中の製品

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

図表

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indications, H2 2020
  • Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..2), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..3), H2 2020
  • Number of Products under Investigation by Universities/Institutes, H2 2020
  • Products under Investigation by Universities/Institutes, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by Actavalon Inc, H2 2020
  • Pipeline by Active Biotech AB, H2 2020
  • Pipeline by Ampio Pharmaceuticals Inc, H2 2020
  • Pipeline by AnTolRx Inc, H2 2020
  • Pipeline by Bayer AG, H2 2020
  • Pipeline by Dermavant Sciences Inc, H2 2020
  • Pipeline by Hercules Pharmaceuticals BV, H2 2020
  • Pipeline by Hutchison MediPharma Ltd, H2 2020
  • Pipeline by Ikena Oncology Inc, H2 2020
  • Pipeline by JAGUAHR Therapeutics Pte Ltd, H2 2020
  • Pipeline by Magenta Therapeutics Inc, H2 2020
  • Pipeline by Pfizer Inc, H2 2020
  • Pipeline by Phenex Pharmaceuticals AG, H2 2020
  • Pipeline by Shenogen Pharma Group Ltd, H2 2020
  • Pipeline by Sol-Gel Technologies Ltd, H2 2020
  • Pipeline by Welichem Biotech Inc, H2 2020
  • Dormant Products, H2 2020
  • Dormant Products, H2 2020 (Contd..1), H2 2020
  • Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Route of Administration, H2 2020
  • Number of Products by Molecule Type, H2 2020
目次
Product Code: GMDHC2616TDB

Summary:

According to the recently published report 'Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 - Pipeline Review, H2 2020'; Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Gamma-aminobutyric acid A receptor, alpha 5 or GABRA5 is a protein encoded by the GABRA5 gene. It mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.

The report 'Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 - Pipeline Review, H2 2020' outlays comprehensive information on the Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 2 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular and Genetic Disorders which include indications Autism, Schizophrenia, Alzheimer's Disease, Anxiety Disorders, Cognitive Disorders, Cognitive Impairment, Cognitive Impairment Associated With Schizophrenia (CIAS), Depression, Down Syndrome, Epilepsy, Ischemic Stroke, Mild Cognitive Impairment, Pervasive Developmental Disorder (PDD) and Traumatic Brain Injury.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5)
  • The report reviews Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Overview
  • Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Companies Involved in Therapeutics Development
  • AgeneBio Inc
  • Anvyl LLC
  • Boehringer Ingelheim International GmbH
  • Cerevel Therapeutics LLC
  • F. Hoffmann-La Roche Ltd
  • Les Laboratoires Servier SAS
  • Ono Pharmaceutical Co Ltd
  • Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Drug Profiles
  • afizagabar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AVL-8168 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • basmisanil - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CVL-865 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ONO-8590580 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RG-7816 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RO-4938581 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RO-7017773 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize GABRA5 for CNS Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize GABRA5 for Schizophrenia and Autism - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonise GABRA5 for Cognitive Impairment - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize GABRA5 for Depression - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Dormant Products
  • Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Discontinued Products
  • Gamma-Aminobutyric Acid Receptor Subunit Alpha 5 (GABA(A) Receptor Subunit Alpha 5 or GABRA5) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.